Upstream Bio Inc. (UPB) is approaching a critical inflection point, with a key clinical data readout anticipated in the near term.
The company's lead drug candidate is Verekitug, being developed as a potential treatment for severe respiratory diseases. It targets the thymic stromal lymphopoietin (TSLP) receptor, a key driver in the inflammatory pathways underlying conditions such as asthma, COPD, and chronic rhinosinusitis with nasal polyps.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.